Araştırma Makalesi
BibTex RIS Kaynak Göster

Preeklampside stathmin-1: klinik şiddetin potansiyel göstergesi

Yıl 2025, Cilt: 6 Sayı: 5, 491 - 495, 24.10.2025

Öz

Amaç
Preeklampsi (PE), anormal plasentasyon ile ilişkili ve belirgin maternal-fetal morbiditeye yol açan multisistemik bir gebelik komplikasyonudur. Plasental disfonksiyonu ve hastalık şiddetini yansıtabilecek güvenilir biyobelirteçlerin tanımlanması klinik açıdan önemlidir. Bu çalışma, hücre proliferasyonu ve trofoblast invazyonunun düzenleyicisi olan Stathmin-1 (STMN-1) düzeylerinin, ciddi özellikleri olan ve olmayan PE olguları ile sağlıklı gebeler arasında karşılaştırılmasını amaçlamıştır.

Yöntemler
Bu prospektif, kesitsel çalışmaya 81 gebe kadın dahil edilmiştir: 41’i PE tanılı (22’si ciddi özellik göstermeyen, 19’u ciddi özellik gösteren) ve 40’ı normotansif sağlıklı kontrol grubundandır. Maternal serum STMN-1 düzeyleri, doğrulanmış bir ELISA yöntemi kullanılarak ölçülmüştür. Klinik özellikler, perinatal sonuçlar ve laboratuvar bulguları gruplar arasında karşılaştırılmıştır.

Bulgular
STMN-1 düzeyleri, PE grubunda (5,99 ± 3,37) kontrol grubuna (8,23 ± 3,42) kıyasla anlamlı olarak daha düşüktü (p = 0,004). Ciddi özellik göstermeyen PE olgularında kontrol grubuna kıyasla STMN-1 düzeyleri daha düşük olma eğiliminde olsa da bu fark istatistiksel olarak anlamlı değildi (p = 0,172). Ciddi özellik gösteren PE olgularında (4,88 ± 2,96), ciddi özellik göstermeyen PE grubuna (6,97 ± 3,46; p = 0,047) ve kontrol grubuna (p = 0,001) kıyasla STMN-1 düzeyleri anlamlı derecede düşüktü.

Sonuç
Maternal serum Stathmin-1 düzeyleri, özellikle ciddi preeklampsi olgularında belirgin şekilde azalmaktadır. Bu bulgular, STMN-1’in PE’nin tanısında ve şiddetinin değerlendirilmesinde potansiyel bir biyobelirteç olarak kullanılabileceğini düşündürmektedir. Bulguların tanısal ve prognostik değerini doğrulamak için daha geniş ölçekli çalışmalara ihtiyaç vardır.

Kaynakça

  • Karrar SA, Martingano DJ, Hong PL. Preeclampsia. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2024.
  • Torres-Torres J, Espino-Y-Sosa S, Martinez-Portilla R, et al. A narrative review on the pathophysiology of preeclampsia. Int J Mol Sci. 2024; 25(14):7569. doi:10.3390/ijms25147569
  • Kim YJ. Pathogenesis and promising non-invasive markers for preeclampsia. Obstet Gynecol Sci. 2013;56(1):2-7. doi:10.5468/OGS.2013. 56.1.2
  • Krzyszkowska M, Staniczek J, Kondracka A, et al. From biomarkers to the molecular mechanism of preeclampsia-a comprehensive literature review. Int J Mol Sci. 2023;24(17):13252. doi:10.3390/ijms241713252
  • Gruslin A, Lemyre B. Pre-eclampsia: fetal assessment and neonatal outcomes. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):491-507. doi: 10.1016/j.bpobgyn.2011.02.004
  • Clement MJ, Jourdain I, Lachkar S, et al. N-terminal stathmin-like peptides bind tubulin and impede microtubule assembly. Biochemistry. 2005;44:14616-14625. doi:10.1021/bi0512492
  • Chen J, Abi-Daoud M, Wang A, et al. Stathmin 1 is a potential novel oncogene in melanoma. Oncogene. 2013;32(10):1330-1337. doi:10.1038/onc.2012.141
  • Yoshie M, Tamura K, Kogo H. Differential localization of decidual stathmin during pregnancy in rats. Placenta. 2004;25(5):449-455. doi: 10.1016/j.placenta.2003.10.007
  • Tian FJ, Qin CM, Li XC, et al. Decreased stathmin-1 expression inhibits trophoblast proliferation and invasion and is associated with recurrent miscarriage. Am J Pathol. 2015;185(10):2709-2721. doi:10.1016/j.ajpath. 2015.06.010
  • Tamura K, Yoshie M, Nishi H, et al. Expression of stathmin in human uterus and decidualizing endometrial stromal cells. Reproduction. 2006; 132(4):625-636. doi:10.1530/rep.1.01148
  • Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol. 2020;135(6):e237-e260. doi:10.1097/AOG. 0000000000003891
  • Brown MA, Magee LA, Kenny LC, et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2018;13:291-310. doi:10.1016/j.preghy.2018.05.004
  • Semerci SY, Yücel B, Erbaş İM, Günkaya OS, Çetinkaya M. The possible association between neonatal morbidities and amniotic fluid pH and electrolyte levels in infants of preeclamptic mothers. Turk J Pediatr. 2021;63(5):867-874. doi:10.24953/turkjped.2021.05.014
  • Fillion A, Guerby P, Menzies D, et al. Pathological investigation of placentas in preeclampsia (the PEARL study). Hypertens Pregnancy. 2021;40(1):56-62. doi:10.1080/10641955.2020.1866008
  • Ali A, Addley S, Ong S. Three-dimensional indices of renal perfusion in normal pregnancy and pre-eclampsia. Ir J Med Sci. 2019;188(1):173-177. doi:10.1007/s11845-018-1844-8
  • Tjoa ML, Oudejans CB, van Vugt JM, Blankenstein MA, van Wijk IJ. Markers for presymptomatic prediction of preeclampsia and intrauterine growth restriction. Hypertens Pregnancy. 2004;23(2):171-189. doi:10.1081/PRG-120028292
  • Larsson N, Marklund U, Gradin HM, Brattsand G, Gullberg M. Control of microtubule dynamics by oncoprotein 18: dissection of the regulatory role of multisite phosphorylation during mitosis. Mol Cell Biol. 1997;17(9):5530-5539. doi:10.1128/MCB.17.9.5530
  • Bièche I, Maucuer A, Laurendeau I, et al. Expression of stathmin family genes in human tissues: non-neural-restricted expression for SCLIP.Genomics. 2003;81(4):400-410. doi:10.1016/s0888-7543(03) 00031-4
  • Nie L, Zhang C, Song H, et al. Overexpression of stathmin 1 predicts poor prognosis and promotes cancer cell proliferation and migration in ovarian cancer. Dis Markers. 2022;2022:3554100. doi:10.1155/2022/ 3554100
  • Watanabe A, Suzuki H, Yokobori T, et al. Stathmin1 regulates p27 expression, proliferation and drug resistance, resulting in poor clinical prognosis in cholangiocarcinoma. Cancer Sci. 2014;105(6):690-696. doi: 10.1111/cas.12417
  • Zhang X, Ji J, Yang Y, Zhang J, Shen L. Stathmin1 increases radioresistance by enhancing autophagy in non-small-cell lung cancer cells. Onco Targets Ther. 2016;9:2565-2574. doi:10.2147/OTT.S100468
  • Yoshie M, Kashima H, Bessho T, Takeichi M, Isaka K, Tamura K. Expression of stathmin, a microtubule regulatory protein, is associated with the migration and differentiation of cultured early trophoblasts. Hum Reprod. 2008;23(12):2766-2774. doi:10.1093/humrep/den317
  • Lin Y, Li C, Shan B, et al. Reduced stathmin-1 expression in natural killer cells associated with spontaneous abortion. Am J Pathol. 2011;178(2): 506-514. doi:10.1016/j.ajpath.2010.10.005
  • Dayanan R, Bulan DD, Yucel KY. Diagnostic and prognostic role of thrombospondin-4 levels in pre-eclampsia: association with onset type, severity, and perinatal outcome. Int J Gynaecol Obstet. 2025;171(1):345-352. doi:10.1002/ijgo.70456

Stathmin-1 as a biomarker in preeclampsia: correlation with clinical severity

Yıl 2025, Cilt: 6 Sayı: 5, 491 - 495, 24.10.2025

Öz

Aims: Preeclampsia (PE) is a multisystem pregnancy disorder linked to abnormal placentation and significant maternal-fetal morbidity. Identifying reliable biomarkers that reflect placental dysfunction and disease severity remains clinically important. This study aimed to assess maternal serum levels of stathmin-1 (STMN-1), a regulator of cell proliferation and trophoblast invasion, in pregnancies complicated by PE with and without severe features, compared to healthy controls.
Methods: This prospective, cross-sectional study included 81 pregnant women: 41 with PE (22 without severe features and 19 with severe features) and 40 normotensive healthy controls. Maternal serum STMN-1 levels were measured using a validated ELISA method. Clinical characteristics, perinatal outcomes, and laboratory findings were compared across groups.
Results: STMN-1 levels were significantly lower in the PE group (5.99±3.37) than in controls (8.23±3.42)(p=0.004). Although not statistically significant (p=0.172), levels tended to be lower in PE without severe features compared to controls. STMN-1 levels were significantly lower in PE with severe features (4.88±2.96) than in PE without severe features (6.97±3.46, p=0.047) and controls (p=0.001).
Conclusion: Maternal serum STMN-1 levels decrease in PE, particularly in severe cases. These findings suggest that STMN1 may serve as a useful biomarker for identifying and assessing the severity of PE. Further large-scale studies are needed to confirm its diagnostic and prognostic value.

Kaynakça

  • Karrar SA, Martingano DJ, Hong PL. Preeclampsia. In: StatPearls. Treasure Island (FL): StatPearls Publishing. 2024.
  • Torres-Torres J, Espino-Y-Sosa S, Martinez-Portilla R, et al. A narrative review on the pathophysiology of preeclampsia. Int J Mol Sci. 2024; 25(14):7569. doi:10.3390/ijms25147569
  • Kim YJ. Pathogenesis and promising non-invasive markers for preeclampsia. Obstet Gynecol Sci. 2013;56(1):2-7. doi:10.5468/OGS.2013. 56.1.2
  • Krzyszkowska M, Staniczek J, Kondracka A, et al. From biomarkers to the molecular mechanism of preeclampsia-a comprehensive literature review. Int J Mol Sci. 2023;24(17):13252. doi:10.3390/ijms241713252
  • Gruslin A, Lemyre B. Pre-eclampsia: fetal assessment and neonatal outcomes. Best Pract Res Clin Obstet Gynaecol. 2011;25(4):491-507. doi: 10.1016/j.bpobgyn.2011.02.004
  • Clement MJ, Jourdain I, Lachkar S, et al. N-terminal stathmin-like peptides bind tubulin and impede microtubule assembly. Biochemistry. 2005;44:14616-14625. doi:10.1021/bi0512492
  • Chen J, Abi-Daoud M, Wang A, et al. Stathmin 1 is a potential novel oncogene in melanoma. Oncogene. 2013;32(10):1330-1337. doi:10.1038/onc.2012.141
  • Yoshie M, Tamura K, Kogo H. Differential localization of decidual stathmin during pregnancy in rats. Placenta. 2004;25(5):449-455. doi: 10.1016/j.placenta.2003.10.007
  • Tian FJ, Qin CM, Li XC, et al. Decreased stathmin-1 expression inhibits trophoblast proliferation and invasion and is associated with recurrent miscarriage. Am J Pathol. 2015;185(10):2709-2721. doi:10.1016/j.ajpath. 2015.06.010
  • Tamura K, Yoshie M, Nishi H, et al. Expression of stathmin in human uterus and decidualizing endometrial stromal cells. Reproduction. 2006; 132(4):625-636. doi:10.1530/rep.1.01148
  • Gestational Hypertension and Preeclampsia: ACOG Practice Bulletin, Number 222. Obstet Gynecol. 2020;135(6):e237-e260. doi:10.1097/AOG. 0000000000003891
  • Brown MA, Magee LA, Kenny LC, et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens. 2018;13:291-310. doi:10.1016/j.preghy.2018.05.004
  • Semerci SY, Yücel B, Erbaş İM, Günkaya OS, Çetinkaya M. The possible association between neonatal morbidities and amniotic fluid pH and electrolyte levels in infants of preeclamptic mothers. Turk J Pediatr. 2021;63(5):867-874. doi:10.24953/turkjped.2021.05.014
  • Fillion A, Guerby P, Menzies D, et al. Pathological investigation of placentas in preeclampsia (the PEARL study). Hypertens Pregnancy. 2021;40(1):56-62. doi:10.1080/10641955.2020.1866008
  • Ali A, Addley S, Ong S. Three-dimensional indices of renal perfusion in normal pregnancy and pre-eclampsia. Ir J Med Sci. 2019;188(1):173-177. doi:10.1007/s11845-018-1844-8
  • Tjoa ML, Oudejans CB, van Vugt JM, Blankenstein MA, van Wijk IJ. Markers for presymptomatic prediction of preeclampsia and intrauterine growth restriction. Hypertens Pregnancy. 2004;23(2):171-189. doi:10.1081/PRG-120028292
  • Larsson N, Marklund U, Gradin HM, Brattsand G, Gullberg M. Control of microtubule dynamics by oncoprotein 18: dissection of the regulatory role of multisite phosphorylation during mitosis. Mol Cell Biol. 1997;17(9):5530-5539. doi:10.1128/MCB.17.9.5530
  • Bièche I, Maucuer A, Laurendeau I, et al. Expression of stathmin family genes in human tissues: non-neural-restricted expression for SCLIP.Genomics. 2003;81(4):400-410. doi:10.1016/s0888-7543(03) 00031-4
  • Nie L, Zhang C, Song H, et al. Overexpression of stathmin 1 predicts poor prognosis and promotes cancer cell proliferation and migration in ovarian cancer. Dis Markers. 2022;2022:3554100. doi:10.1155/2022/ 3554100
  • Watanabe A, Suzuki H, Yokobori T, et al. Stathmin1 regulates p27 expression, proliferation and drug resistance, resulting in poor clinical prognosis in cholangiocarcinoma. Cancer Sci. 2014;105(6):690-696. doi: 10.1111/cas.12417
  • Zhang X, Ji J, Yang Y, Zhang J, Shen L. Stathmin1 increases radioresistance by enhancing autophagy in non-small-cell lung cancer cells. Onco Targets Ther. 2016;9:2565-2574. doi:10.2147/OTT.S100468
  • Yoshie M, Kashima H, Bessho T, Takeichi M, Isaka K, Tamura K. Expression of stathmin, a microtubule regulatory protein, is associated with the migration and differentiation of cultured early trophoblasts. Hum Reprod. 2008;23(12):2766-2774. doi:10.1093/humrep/den317
  • Lin Y, Li C, Shan B, et al. Reduced stathmin-1 expression in natural killer cells associated with spontaneous abortion. Am J Pathol. 2011;178(2): 506-514. doi:10.1016/j.ajpath.2010.10.005
  • Dayanan R, Bulan DD, Yucel KY. Diagnostic and prognostic role of thrombospondin-4 levels in pre-eclampsia: association with onset type, severity, and perinatal outcome. Int J Gynaecol Obstet. 2025;171(1):345-352. doi:10.1002/ijgo.70456
Toplam 24 adet kaynakça vardır.

Ayrıntılar

Birincil Dil İngilizce
Konular Kadın Hastalıkları ve Doğum
Bölüm Research Articles [en] Araştırma Makaleleri [tr]
Yazarlar

Zeynep Kayaoğlu Yıldırım 0000-0002-2582-7675

Gökhan Bolluk 0000-0002-3506-6806

Oğuzhan Zengi 0000-0002-4614-5235

Yayımlanma Tarihi 24 Ekim 2025
Gönderilme Tarihi 13 Ağustos 2025
Kabul Tarihi 13 Eylül 2025
Yayımlandığı Sayı Yıl 2025 Cilt: 6 Sayı: 5

Kaynak Göster

AMA Kayaoğlu Yıldırım Z, Bolluk G, Zengi O. Stathmin-1 as a biomarker in preeclampsia: correlation with clinical severity. J Med Palliat Care / JOMPAC / Jompac. Ekim 2025;6(5):491-495.

images?q=tbn:ANd9GcRrI_RWgGRe7JRpz3PAnkt2YEFD2l6WEmgHMzuM2w9b&s

f9ab67f.png     

7yziemq.png




COPE.jpg

icmje_1_orig.png

cc.logo.large.png

ncbi.png

ORCID_logo.png

images?q=tbn:ANd9GcQk2AsOdjP67NBkYAqd8FHwCmh0_3dkMrXh3mFtfPKXwIai7h0lIds8QYM9YjKMhZw8iP0&usqp=CAU

logo_world_of_journals_no_margin.png1280px-WorldCat_logo.svg.png                             images?q=tbn:ANd9GcRrI_RWgGRe7JRpz3PAnkt2YEFD2l6WEmgHMzuM2w9b&s


Dergimiz; TR-Dizin ULAKBİM, ICI World of  Journal's, Index Copernicus, Directory of Research Journals Indexing (DRJI), General Impact Factor, Google Scholar, Researchgate, WorldCat (OCLC), CrossRef (DOI), ROAD, ASOS İndeks, Türk Medline İndeks, Eurasian Scientific Journal Index (ESJI) ve Türkiye Atıf Dizini'nde indekslenmektedir.

EBSCO, DOAJ, OAJI, ProQuest dizinlerine müracaat yapılmış olup, değerlendirme aşamasındadır.

Makaleler "Çift-Kör Hakem Değerlendirmesi”nden geçmektedir.

Üniversitelerarası Kurul (ÜAK) Eşdeğerliği: Ulakbim TR Dizin'de olan dergilerde yayımlanan makale [10 PUAN] ve 1a, b, c hariç uluslararası indekslerde (1d) olan dergilerde yayımlanan makale [5 PUAN].

Note: Our journal is not WOS indexed and therefore is not classified as Q.

You can download Council of Higher Education (CoHG) [Yüksek Öğretim Kurumu (YÖK)] Criteria) decisions about predatory/questionable journals and the author's clarification text and journal charge policy from your browser.  About predatory/questionable journals and journal charge policy

Not: Dergimiz WOS indeksli değildir ve bu nedenle Q  sınıflamasına dahil değildir.
Yağmacı/şüpheli dergilerle ilgili Yüksek Öğretim Kurumu (YÖK) kararları ve yazar açıklama metni ile dergi ücret politikası: Yağmacı/Şaibeli Dergiler ve Dergi Ücret Politikası